昭衍新药

- 603127

-

-  -

-
昨收盘:- 今开盘:- 最高价:- 最低价:-
市值:-亿元 流通:- 成交:-手 换手:-
历年数据:  2024  2023  2022  2021  2020  2019  2018  2017  2016  2015  2014 
昭衍新药(603127) 利润表
单位:万元
报表日期2024-03-312023-12-312023-09-302023-06-302023-03-31
一、营业总收入32,480.91237,648.68158,707.98101,207.7336,938.60
营业收入32,480.91237,648.68158,707.98101,207.7336,938.60
二、营业总成本29,329.46162,201.02110,483.7271,419.6626,281.13
营业成本21,815.70136,370.1189,245.5656,350.9717,843.00
营业税金及附加236.97767.61574.08330.04166.51
销售费用585.052,461.511,833.261,186.61536.12
管理费用7,196.1728,025.4822,923.6815,249.297,454.38
财务费用-2,801.15-15,109.12-11,856.83-7,390.60-2,480.03
研发费用2,296.739,685.447,763.975,693.342,761.16
资产减值损失----------
公允价值变动收益-31,001.29-24,564.15-10,851.39-19,767.099,844.16
投资收益697.20962.78714.17584.3551.41
其中:对联营企业和合营企业的投资收益-55.87-306.92-255.31-167.90-76.99
汇兑收益----------
三、营业利润-29,300.8350,709.6339,208.4911,683.9121,436.97
加:营业外收入1.0438.6723.5922.192.14
减:营业外支出13.2153.2633.5712.546.21
其中:非流动资产处置损失----------
四、利润总额-29,313.0050,695.0439,198.5211,693.5721,432.89
减:所得税费用-1,976.6411,539.796,578.822,742.752,661.88
五、净利润-27,336.3639,155.2632,619.708,950.8218,771.01
归属于母公司所有者的净利润-27,222.2539,699.2632,759.849,062.7218,775.97
少数股东损益-114.11-544.00-140.14-111.90-4.96
六、每股收益
基本每股收益(元/股)-0.36000.53000.44000.17000.3500
稀释每股收益(元/股)-0.36000.53000.44000.17000.3500
七、其他综合收益86.38496.081,018.421,325.21-440.26
八、综合收益总额-27,249.9839,651.3333,638.1210,276.0318,330.74
归属于母公司所有者的综合收益总额-27,135.8740,195.3333,778.2610,387.9318,335.70
归属于少数股东的综合收益总额-114.11-544.00-140.14-111.90-4.96
下载全部历史数据到excel中 返回页顶